Development of the Nurochek Pro
Project description and overview:
The purpose of this project is to develop the “Nurochek Pro” brain injury assessment device which is a clinical console extension model of the basic Nurochek device so that it can be used in clinical and mobile settings in the US health system. In addition, the company is in discussions with various sporting bodies in Australia i.e. AFL, ARL, and ARU for mobile applications.
Headsafe IP has developed a fast, portable, affordable and objective test of brain function, essentially a “brain scanner in a briefcase”. This portable headset uses clinically validated technology to measure the brain’s electrical activity and send results to a smart device for analysis and to the cloud for secure, online (HIPAA and GDPR compliant) storage. In a two-minute assessment Nurochek Pro will demonstrate when a result differs from a previously obtained base reading of the patient’s brain electrical activity and also when it has returned to the previous base reading following an injury, so that patients can resume normal activity.
The device will enable fast and reliable diagnosis without the need for expensive equipment or time delays whilst patients are transported to test equipment. To function effectively in the clinical context, the Nurochek Pro briefcase must be self-standing, robust, water and weatherproof with additional battery storage to power both the headset and an integrated screen to make it more suitable for use outside the hospital and easy to integrate into hospital IT systems.
This solution has multiple platform applications with target markets being:
- Sports related concussion
- Traumatic brain injury from falls
- Motor vehicle accidents
- In-field military incidents
- Early stage diagnosis of other acute and chronic brain conditions
The company has their own data analysis team and a Machine Learning project with Western Sydney University to refine these metrics further. They are also undertaking studies to screen out confounding factors like fatigue (cognitive and mental), hydration state, blood glucose levels, sleep deprivation etc. to further increase the specificity of their test.
This project will ensure that the manufacturing of the medical device remains in Australia and that IP is also retained.
- Increased collaboration with other manufacturers
- Increased spending on R&D
- Increased information and communication technology (ICT) intensity
- Increased number of staff with science, technology, engineering, and maths (STEM) skills
- Larger patent portfolio
- Better qualified employee
- Greater share of services in total revenue
- Higher product value density (by weight)
- Higher trade intensity
- More extensive backward links
- Larger geographical reach
- HeadsafeIP forecast $83.6M in revenue over the next 5 years
- HeadsafeIP plan to employ 17 new staff during the project and within one year of project completion
Government Funds: $447,500 | Industry: $447,500